Beam Historical Income Statement
| BEAM Stock | USD 27.37 0.17 0.63% |
Historical analysis of Beam Therapeutics income statement accounts such as Interest Expense of 49 M, Selling General Administrative of 122.7 M or Other Operating Expenses of 581.9 M can show how well Beam Therapeutics performed in making a profits. Evaluating Beam Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Beam Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Beam Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Beam Therapeutics is a good buy for the upcoming year.
Beam |
About Beam Income Statement Analysis
Beam Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Beam Therapeutics shareholders. The income statement also shows Beam investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Beam Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Beam Therapeutics. It is also known as Beam Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on Beam Therapeutics income statement and represents the costs associated with goods and services Beam Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most accounts from Beam Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Beam Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.At this time, Beam Therapeutics' Total Other Income Expense Net is very stable compared to the past year. As of the 1st of December 2024, Income Tax Expense is likely to grow to about 1.4 M, though Gross Profit is likely to grow to (56.7 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 444.3M | 399.4M | 554.2M | 581.9M | Cost Of Revenue | 16.4M | 22.6M | 437.4M | 459.3M |
Beam Therapeutics income statement Correlations
Click cells to compare fundamentals
Beam Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Beam Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 5.4M | 9.5M | 16.4M | 22.6M | 20.0M | 11.7M | |
| Interest Expense | 187K | 1.6M | 9K | 15.3M | 46.7M | 49.0M | |
| Selling General Administrative | 20.6M | 29.6M | 57.2M | 87.8M | 116.8M | 122.7M | |
| Gross Profit | (5.4M) | (103.2M) | 35.4M | 38.3M | (59.7M) | (56.7M) | |
| Other Operating Expenses | 75.2M | 132.8M | 444.3M | 399.4M | 554.2M | 581.9M | |
| Operating Income | (75.2M) | (132.8M) | (392.5M) | (338.5M) | (176.5M) | (185.3M) | |
| Ebit | (74.6M) | (137.5M) | (408.9M) | (346.9M) | (176.5M) | (185.3M) | |
| Research Development | 54.6M | 103.2M | 387.1M | 311.6M | 437.4M | 459.3M | |
| Ebitda | (69.2M) | (128.0M) | (392.5M) | (324.3M) | (156.5M) | (164.3M) | |
| Cost Of Revenue | 5.4M | 103.2M | 16.4M | 22.6M | 437.4M | 459.3M | |
| Total Operating Expenses | 75.2M | 132.8M | 444.3M | 399.4M | 554.2M | 581.9M | |
| Income Before Tax | (78.3M) | (194.6M) | (370.6M) | (260.2M) | (131.2M) | (137.7M) | |
| Total Other Income Expense Net | (3.2M) | (61.8M) | 21.8M | 78.3M | 45.3M | 47.6M | |
| Net Income | (78.4M) | (256.4M) | (341.4M) | (263.6M) | (132.5M) | (139.2M) | |
| Income Tax Expense | 116K | 61.8M | (29.3M) | 3.4M | 1.4M | 1.4M | |
| Net Interest Income | 2.3M | 1.6M | (9K) | 15.3M | 42.2M | 44.3M | |
| Total Revenue | 18K | 24K | 51.8M | 60.9M | 377.7M | 396.6M | |
| Net Income From Continuing Ops | (78.3M) | (194.6M) | (370.6M) | (289.1M) | (313.7M) | (329.4M) | |
| Reconciled Depreciation | 3.5M | 4.7M | 7.5M | 14.1M | 18.6M | 19.5M | |
| Net Income Applicable To Common Shares | (91.0M) | (195.9M) | (370.6M) | (260.2M) | (234.2M) | (245.9M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.58) | Revenue Per Share 4.273 | Quarterly Revenue Growth (0.17) | Return On Assets (0.09) | Return On Equity (0.18) |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.